Tesla Unveils Driverless Cybercab: First Public Rides Set for Sept. 3 in Austin

http://wealthcreation.clubLeave a comment
Tesla (TSLA) will host an invite-only, livestreamed Cybercab launch event on September 3 in Austin, Texas, offering public rides in a more expansive demonstration than its October 2024 “We, Robot” showcase. The Cybercab is Tesla’s first dedicated autonomous ride-hailing vehicle, a compact two-seater built without a steering wheel or pedals and powered by a front-mounted AC three-phase permanent-magnet motor delivering about 163 kW (219 hp) through a single-speed reduction gear. It reportedly uses a 47.6–48.0 kWh lithium-ion battery pack (nominal 326 V, 146 Ah) and is expected to support inductive wireless charging, enabling the autonomous fleet to reposition and recharge without human intervention.

Follow Smart Investors

http://wealthcreation.clubLeave a comment
💥 Alpha Binwani Capital Newsletter
Smart investors are already reading it. Join them.

•🔵 Trusted by Bloomberg & Reuters — Research relied on by global financial leaders

•🟢 Real-Time Market Edge — Timely insights and expert trend analysis

•🟠 Exclusive Strategies — High-value ideas and deep dives, now free

•🟣 Zero Cost — Premium intelligence with no fees or hidden catch

•🟡 Stay Ahead — Institutional-level insights delivered to your inbox

Join the professionals shaping smarter market moves.

Subscribe free: bit.ly/FreeAlphaNewsletter

#Finance #Investing #MarketInsights #WealthBuilding #Alpha #SmartMoney #FinancialIntelligence

Mounjaro’s CV Nod: Lilly’s 8% MACE Edge Over Trulicity Rewrites GLP-1 Cardiovascular Standards

http://wealthcreation.clubLeave a comment
💉 Eli Lilly has won FDA approval for Mounjaro to reduce the risk of major adverse cardiovascular events (MACE)—including cardiovascular death, heart attack and stroke—in adults with Type 2 diabetes, a population in which roughly one in three also has undetected cardiovascular disease. The label is underpinned by the phase 3 SURPASS-CVOT trial, a four-year, 13,000-patient study across 30 countries that marked the first head-to-head cardiovascular outcomes comparison between two incretin drugs rather than a placebo-controlled design. In SURPASS-CVOT, Mounjaro demonstrated non-inferiority to Lilly’s earlier GLP-1 franchise leader Trulicity and delivered an 8% lower rate of MACE versus Trulicity, which itself gained a cardiovascular-risk-reduction indication in 2020 after its 2014 diabetes approval